A study testing whether a new weekly shot, tirzepatide, can help survivors of acute lymphoblastic leukemia lose weight.

Recruiting now. Registry record last updated June 4, 2026.

Who can join: Adults 18+, are survivors of acute lymphoblastic leukemia, BMI 27+.
What you take: tirzepatide, given as part of the study. Check ClinicalTrials.gov for this trial's study groups, including any placebo or comparison medicine.
How long it lasts: The full study runs about 2.6 years; your own time in it is usually shorter.
What you get: Many clinical trials pay for the study medication and the study visits. Some also pay for travel. Ask the study team what this one covers before you sign the consent form.

This one may not fit you. We check your age, where you live, and the rules each study sets, then show the clinical trials that do.

Check my fit →

Phase Phase 2Sponsor St. Jude Children's Research HospitalDrug tirzepatideClass GLP-1/GIPSites 1 USEnrollment target 20

What this study is for

Primary condition: Acute Lymphoblastic Leukemia. Also studied in: Obesity.

Full scientific study title: Resistance Exercise and Incretin Mimetic for Cardiometabolic Health in Survivors of ALL With Obesity.

Who can join

Age18 and upSexAnyBMI27 or higher

Adults 18+, are survivors of acute lymphoblastic leukemia, BMI 27+. A site coordinator confirms whether you qualify during a free screening visit. The exact medical requirements are below.

Full medical eligibility (for you and your doctor)verbatim from the registry

This is the exact wording from ClinicalTrials.gov, including clinical measures (lab values, imaging scores). Bring it to your doctor if any of it is unclear.

Key inclusion criteria

≥5 years from diagnosis of acute lymphoblastic leukemia (ALL) treated with chemotherapy only
≥2 years from completion of therapy
Participant has a negative (urine or blood) pregnancy test (if female)
Age ≥18 years at the time of enrollment
Participant has obesity (BMI \> 30kg/m2) or overweight (BMI \> 27kg/m2) with ≥1 weight related co-morbidity (hypertension, dyslipidemia, obstructive sleep apnea, cardiovascular disease)

Key exclusion criteria

Participant has known diabetes or is found at baseline to have laboratory evidence of diabetes including HbA1c ≥ 6.5%
Participant is using or has used weight management medication in the past 3 months or had recent significant weight loss \> 5kg in the last 3 months Severe renal dysfunction (eGFR \<30 mL/min/1.73 m²)
Saxenda® (liraglutide 3.0 mg)
Xenical®/Alli® (orlistat)
Meridia® (sibutramine)

Where this trial is enrolling

This trial has 1 sites across 1 state. Contact a site coordinator directly to start screening.

Tennessee1 site

St. Jude Children's Research Hospital
Memphis, Tennessee
Stephanie B Dixon, MD, MPH888-226-4343referralinfo@stjude.org

Follow this trial

We email you if NCT07228741 changes status, adds new sites in your state, or if a similar trial opens for the same condition. No spam, opt out any time.

Timeline

Started enrolling: April 23, 2026. Expected completion: November 2028. Last updated on ClinicalTrials.gov: June 4, 2026.

Official source

Every Monday we check this trial against ClinicalTrials.gov, the federal registry for clinical research. Last checked August 21, 2026. Confirm the current status there before you contact a site:

View on ClinicalTrials.gov →

Back to the full directory → or take the matching quiz if you want clinical trials filtered to your conditions and location.

John Samaras, Founder and EditorI started GLP Chart after overpaying for a GLP-1 myself. Based in Austin, Texas.
About this site · LinkedIn · Contact

Why you can trust GLP Chart. Same scoring framework applied to every program. No paid placements. We never remove unfavorable information at an advertiser's request. Pricing is pulled from each program's public-facing page every Monday.